Success Metrics

Clinical Success Rate
85.8%

Based on 224 completed trials

Completion Rate
86%(224/261)
Active Trials
31(9%)
Results Posted
38%(84 trials)
Terminated
37(11%)

Phase Distribution

Ph early_phase_1
7
2%
Ph phase_2
111
34%
Ph phase_1
60
18%
Ph phase_4
24
7%
Ph phase_3
57
17%
Ph not_applicable
71
22%

Phase Distribution

67

Early Stage

111

Mid Stage

81

Late Stage

Phase Distribution330 total trials
Early Phase 1First-in-human
7(2.1%)
Phase 1Safety & dosage
60(18.2%)
Phase 2Efficacy & side effects
111(33.6%)
Phase 3Large-scale testing
57(17.3%)
Phase 4Post-market surveillance
24(7.3%)
N/ANon-phased studies
71(21.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.4%

224 of 272 finished

Non-Completion Rate

17.6%

48 ended early

Currently Active

31

trials recruiting

Total Trials

330

all time

Status Distribution
Active(42)
Completed(224)
Terminated(48)
Other(16)

Detailed Status

Completed224
Terminated37
Recruiting22
unknown16
Withdrawn11
Not yet recruiting10

Development Timeline

Analytics

Development Status

Total Trials
330
Active
31
Success Rate
85.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 17 (2.1%)
Phase 160 (18.2%)
Phase 2111 (33.6%)
Phase 357 (17.3%)
Phase 424 (7.3%)
N/A71 (21.5%)

Trials by Status

active_not_recruiting93%
enrolling_by_invitation10%
recruiting227%
terminated3711%
completed22468%
not_yet_recruiting103%
unknown165%
withdrawn113%

Recent Activity

Clinical Trials (330)

Showing 20 of 330 trialsScroll for more
NCT06641466Phase 3

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Recruiting
NCT07565675Not Applicable

The BALANCE Study - Improving Glucose Control Through Prebiotic Gut Health Drink in Postmenopausal Women

Not Yet Recruiting
NCT04745299Phase 3

Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS

Completed
NCT07102459Phase 2

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

Completed
NCT06862791Phase 2

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Active Not Recruiting
NCT05683834Phase 1

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Completed
NCT07529262Phase 3

Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial

Not Yet Recruiting
NCT04627922Phase 4

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use

Completed
NCT06671938Phase 2

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

Active Not Recruiting
NCT06582706Phase 1

Nicotinic Acid for the Treatment of Alzheimer's Disease

Recruiting
NCT06101745Phase 2

Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

Recruiting
NCT07264517Phase 2

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Recruiting
NCT03482479Phase 2

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

Completed
NCT03456063Phase 3

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Completed
NCT07344727Not Applicable

Impact of Haskap Berries on Recovery From High Intensity Resistance Training

Recruiting
NCT06967259Phase 1

ENA-001 for Opioid Induced Respiratory Depression

Active Not Recruiting
NCT05247255Early Phase 1

Quadratus Lumborum Block for Total Hip Arthroplasty

Recruiting
NCT07304791Phase 1

This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects

Recruiting
NCT05764057Phase 3

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

Recruiting
NCT06595238Phase 2

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

Completed

Drug Details

Intervention Type
DRUG
Total Trials
330